中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
7期
153-155
,共3页
布地奈德%孟鲁司特钠%慢性阻塞性肺疾病%IL-6%IL-8%TNF-α
佈地奈德%孟魯司特鈉%慢性阻塞性肺疾病%IL-6%IL-8%TNF-α
포지내덕%맹로사특납%만성조새성폐질병%IL-6%IL-8%TNF-α
budesonide%montelukast%COPD%IL-6%IL-8%TNF-α
目的：探讨布地奈德联合孟鲁司特钠对慢性阻塞性肺病（chronic obstructive pulmonary disease，COPD）患者肺功能及血清中白细胞介素-6（IL-6）、白细胞介素-8（IL-8）和肿瘤坏死因子（TNF-α）水平的影响，分析其临床效果。方法选取2012年4月～2013年12月瑞安市中医院收治的120例COPD患者，随机均分为观察组和对照组（n＝60），观察组采用在常规治疗基础上加用布地奈德联合孟鲁司特钠治疗，对照组在常规治疗基础上加用布地奈德治疗。治疗前、后测定2组患者的肺功能，并检测患者血清中IL-6、IL-8和TNF-α水平。结果观察组的疗效显著优于对照组（P＜0.05）；治疗后观察组的用力肺活量（forced vital capacity，FVC）、第一秒用力呼气容积（forced expiratory volume in one second，FEV1）、最大呼气中期流速（maximum midexpiratory flow，MMEF）和呼气峰流速（peak expiratory flow，PEF）均显著大于对照组（P＜0.05）；观察组与对照组在治疗后血清中IL-6、I L-8和TNF-α的表达均较治疗前明显降低，但2组相比，经治疗后观察组的下降更明显，2组比较差异具有统计学意义（P＜0.05）。结论布地奈德联合孟鲁司特钠治疗COPD疗效明显，可通过减少细胞因子释放，控制气道炎症发生，改善肺功能。
目的：探討佈地奈德聯閤孟魯司特鈉對慢性阻塞性肺病（chronic obstructive pulmonary disease，COPD）患者肺功能及血清中白細胞介素-6（IL-6）、白細胞介素-8（IL-8）和腫瘤壞死因子（TNF-α）水平的影響，分析其臨床效果。方法選取2012年4月～2013年12月瑞安市中醫院收治的120例COPD患者，隨機均分為觀察組和對照組（n＝60），觀察組採用在常規治療基礎上加用佈地奈德聯閤孟魯司特鈉治療，對照組在常規治療基礎上加用佈地奈德治療。治療前、後測定2組患者的肺功能，併檢測患者血清中IL-6、IL-8和TNF-α水平。結果觀察組的療效顯著優于對照組（P＜0.05）；治療後觀察組的用力肺活量（forced vital capacity，FVC）、第一秒用力呼氣容積（forced expiratory volume in one second，FEV1）、最大呼氣中期流速（maximum midexpiratory flow，MMEF）和呼氣峰流速（peak expiratory flow，PEF）均顯著大于對照組（P＜0.05）；觀察組與對照組在治療後血清中IL-6、I L-8和TNF-α的錶達均較治療前明顯降低，但2組相比，經治療後觀察組的下降更明顯，2組比較差異具有統計學意義（P＜0.05）。結論佈地奈德聯閤孟魯司特鈉治療COPD療效明顯，可通過減少細胞因子釋放，控製氣道炎癥髮生，改善肺功能。
목적：탐토포지내덕연합맹로사특납대만성조새성폐병（chronic obstructive pulmonary disease，COPD）환자폐공능급혈청중백세포개소-6（IL-6）、백세포개소-8（IL-8）화종류배사인자（TNF-α）수평적영향，분석기림상효과。방법선취2012년4월～2013년12월서안시중의원수치적120례COPD환자，수궤균분위관찰조화대조조（n＝60），관찰조채용재상규치료기출상가용포지내덕연합맹로사특납치료，대조조재상규치료기출상가용포지내덕치료。치료전、후측정2조환자적폐공능，병검측환자혈청중IL-6、IL-8화TNF-α수평。결과관찰조적료효현저우우대조조（P＜0.05）；치료후관찰조적용력폐활량（forced vital capacity，FVC）、제일초용력호기용적（forced expiratory volume in one second，FEV1）、최대호기중기류속（maximum midexpiratory flow，MMEF）화호기봉류속（peak expiratory flow，PEF）균현저대우대조조（P＜0.05）；관찰조여대조조재치료후혈청중IL-6、I L-8화TNF-α적표체균교치료전명현강저，단2조상비，경치료후관찰조적하강경명현，2조비교차이구유통계학의의（P＜0.05）。결론포지내덕연합맹로사특납치료COPD료효명현，가통과감소세포인자석방，공제기도염증발생，개선폐공능。
Objective To explore the effect and lung function of the budesonide combined with montelukast for treatment of chronic obstructive pulmonary disease(COPD)and the effect on serum IL-6,IL-8 and TNF-α.Methods 120 patients with COPD in our hospital from April 2012 to December 2013 were randomly divided into observation group and control group (n =60 ).Observation group was given budesonide combined with montelukast on the basis of general routine treatment and control group was given budesonide on the basis of general routine treatment.The lung function and the level of IL-6、IL-8 and TNF-αin serum were detected berore and after treatment.Results The efficacy in observation group was significantly better than that in control group(P<0.05).The forced vital capacity(FVC),forced expiratory volume in one second(FEV1),maximal mid expiratory flow(MMEF),and peak expiratory flow(PEF)in the observation group were significantly higher than those in the control group(P<0.05 ).In addition, after treatment the levels of IL-6,IL-8 and TNF-αexpression in serum of the observation group and control group were significantly lower than before treatment,but the levels of the observation group after treatment was significantly lower than the control group,the difference were statistically significant (P<0.05).Conclusion The efficacy of the budesonide combined with montelukast for treatment of COPD is exact by reducing cytokine release, controling airway inflammation to improve the lung function.It is worthy to be popularized.
